OtherClinical Investigations (Human)
Impact of 18F-FET PET/MR on clinical management of brain tumor patients
Cornelia Brendle, Caroline Maier, Benjamin Bender, Jens Schittenhelm, Frank Paulsen, Mirjam Renovanz, Constantin Roder, Salvador Castaneda-Vega, Ghazaleh Tabatabai, Ulrike Ernemann and Christian la Fougère
Journal of Nuclear Medicine August 2021, jnumed.121.262051; DOI: https://doi.org/10.2967/jnumed.121.262051
Cornelia Brendle
1 University hospital Tuebingen, Germany;
Caroline Maier
1 University hospital Tuebingen, Germany;
Benjamin Bender
1 University hospital Tuebingen, Germany;
Jens Schittenhelm
1 University hospital Tuebingen, Germany;
Frank Paulsen
1 University hospital Tuebingen, Germany;
Mirjam Renovanz
1 University hospital Tuebingen, Germany;
Constantin Roder
1 University hospital Tuebingen, Germany;
Salvador Castaneda-Vega
1 University hospital Tuebingen, Germany;
Ghazaleh Tabatabai
1 University hospital Tuebingen, Germany;
Ulrike Ernemann
1 University hospital Tuebingen, Germany;
Christian la Fougère
2 Universityhospital Tuebingen

Article Figures & Data
Additional Files
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 66, Issue 6
June 1, 2025
Impact of 18F-FET PET/MR on clinical management of brain tumor patients
Cornelia Brendle, Caroline Maier, Benjamin Bender, Jens Schittenhelm, Frank Paulsen, Mirjam Renovanz, Constantin Roder, Salvador Castaneda-Vega, Ghazaleh Tabatabai, Ulrike Ernemann, Christian la Fougère
Journal of Nuclear Medicine Aug 2021, jnumed.121.262051; DOI: 10.2967/jnumed.121.262051
Impact of 18F-FET PET/MR on clinical management of brain tumor patients
Cornelia Brendle, Caroline Maier, Benjamin Bender, Jens Schittenhelm, Frank Paulsen, Mirjam Renovanz, Constantin Roder, Salvador Castaneda-Vega, Ghazaleh Tabatabai, Ulrike Ernemann, Christian la Fougère
Journal of Nuclear Medicine Aug 2021, jnumed.121.262051; DOI: 10.2967/jnumed.121.262051
Jump to section
Related Articles
Cited By...
- An External, Independent Validation of an O-(2-[18F]Fluoroethyl)-L-Tyrosine PET Automatic Segmentation Network on a Single-Center, Prospective Dataset of Patients with Glioblastoma
- Amino Acid PET in Neurooncology
- Hybrid 18F-Fluoroethyltyrosine PET and MRI with Perfusion to Distinguish Disease Progression from Treatment-Related Change in Malignant Brain Tumors: The Quest to Beat the Toughest Cases
- Amino Acid PET in Neurooncology
- Amino Acid Tracer PET MRI in Glioma Management: What a Neuroradiologist Needs to Know